C3orf17 Inhibitors
C3orf17 inhibitors encompass a diverse array of chemical compounds that, through their unique interactions with various signaling pathways, collectively contribute to a reduction in the functional activity of the protein C3orf17. For instance, the MEK inhibitors PD 98059 and U0126 attenuate the MAPK/ERK signaling cascade, a pathway that, when inhibited, would logically lead to a decrease in the activity of C3orf17 if it is regulated by ERK dynamics. Similarly, LY294002 and Rapamycin target the PI3K/AKT and mTOR pathways, respectively; these compounds would curtail C3orf17 activity if it is contingent on signaling through these routes. SB 203580 and SP600125 serve as specific inhibitors for p38 MAP kinase and JNK, which are integral to stress responses and inflammatory pathways; their inhibition would likely down-regulate C3orf17 if it functions within these pathways. The NUAK1 inhibitor WZ8040, the MEK5 inhibitor U0126, and the EGFR inhibitor Gefitinib each could potentially suppress C3orf17 activity by modulating specific kinase-driven signaling networks that C3orf17 may be part of.
The specificity of these inhibitors extends to other cellular processes as well. Y-27632 disrupts the Rho-associated kinase (ROCK) pathway, potentially diminishing C3orf17 activity if it relies on the cytoskeletal organization and cellular tension regulated by ROCK. The broad-spectrum PKC inhibitor Go 6983 would likely impinge upon C3orf17 function if PKC signaling affects it. ML7, by inhibiting myosin light chain kinase (MLCK), could decrease C3orf17 activity if cellular motility and contraction mechanisms impact its function. Each inhibitor's mechanism underscores a potential point of intervention within cellular signaling networks where C3orf17 activity could be influenced, illustrating a multifaceted approach to diminishing the protein's function through indirect modulation of its signaling environment.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a potent and selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is a part of the MAPK/ERK pathway. By inhibiting MEK, PD 98059 can indirectly diminish C3orf17 activity if C3orf17 function is regulated by ERK signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a synthetic molecule that inhibits phosphoinositide 3-kinases (PI3K). If C3orf17 is involved in PI3K/AKT signaling, the inhibition of PI3K by LY294002 would lead to a decrease in AKT activity, thereby reducing C3orf17 functional activity if it is AKT-dependent. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase. If C3orf17 plays a role in the stress response regulated by p38 MAPK, the use of SB 203580 would suppress this pathway, possibly leading to the diminished activity of C3orf17. | ||||||
WZ8040 | 1214265-57-2 | sc-364656 sc-364656A | 5 mg 10 mg | $255.00 $480.00 | ||
WZ8040 is a selective inhibitor of the NUAK family kinase (NUAK1), which may be involved in cellular stress and metabolism. If C3orf17's activity is modulated through NUAK1 pathways, inhibition by WZ8040 could lead to a reduction in C3orf17 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. If C3orf17 is involved in pathways downstream of mTOR, such as cell growth and proliferation, rapamycin could diminish C3orf17 activity by inhibiting mTOR-dependent signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If C3orf17 function is linked to pathways involving JNK, such as apoptosis or inflammation, then SP600125 could indirectly lead to decreased C3orf17 function by inhibiting JNK activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated kinase (ROCK). If C3orf17 is implicated in cellular processes regulated by ROCK, such as cytoskeletal organization, Y-27632 would reduce ROCK activity and potentially decrease C3orf17 function. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go 6983 is a pan-protein kinase C (PKC) inhibitor. If C3orf17 function is tied to PKC-mediated pathways, Go 6983 could inhibit PKC activity, thereby diminishing the activity of C3orf17. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML7 is an inhibitor of myosin light chain kinase (MLCK). If C3orf17 activity is associated with cellular contraction and motility mediated by MLCK, then ML7 would diminish C3orf17 function by inhibiting MLCK activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. If C3orf17 function is downstream of EGFR, then inhibiting EGFR with Gefitinib would reduce signaling through this pathway, potentially leading to a decrease in C3orf17 activity. | ||||||